Understand the source comparison
Best LIPO-C Dosage for Inositol: Protocol Comparison
Maintenance (Metabolically Healthy) 25–50mg 1–2× weekly Fasting glucose <100mg/dL, normal liver enzymes, HOMA-IR <2.0 30–50% above baseline Adequate for phosphatidylinositol turnover support without saturating pathways. Appropriate when lipotropic function is
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Maintenance (Metabolically Healthy)
- 25–50mg
- 1–2× weekly
- Fasting glucose <100mg/dL, normal liver enzymes, HOMA-IR <2.0
- 30–50% above baseline
- Adequate for phosphatidylinositol turnover support without saturating pathways. Appropriate when lipotropic function is already normal
- Moderate Intervention (Insulin Resistance)
- 50–75mg
- 2× weekly
- Fasting glucose 100–125mg/dL, HOMA-IR 2.0–3.5, mildly elevated liver enzymes
- 60–80% above baseline
- Compensates for reduced cellular uptake efficiency in early metabolic dysfunction. Threshold dose for measurable VLDL synthesis acceleration
- Therapeutic (Hepatic Steatosis)
- 75–100mg
- 2–3× weekly
- Confirmed NAFLD, HOMA-IR >3.5, ALT >40 U/L
- 90–120% above baseline
- Required to saturate impaired uptake mechanisms and provide substrate for aggressive hepatic lipid export. Clinical trial dosing standard
- High-Dose (Off-Label Research)
- 100–150mg
- 3× weekly
- Severe metabolic syndrome, BMI >35, persistent hepatic steatosis despite standard dosing
- 120–150% above baseline
- Exceeds typical therapeutic range. Marginal additional benefit beyond 100mg in most patients, used only when lower doses demonstrate inadequate response